GlaxoSmithKline - Articles and news items

GSK injects $60 million and 58 jobs into Victoria

Industry news, News / 6 February 2012 / F T I Consulting

GlaxoSmithKline Pty Ltd (GSK) announced today that it will invest $60 million to expand its manufacturing and new drug development activities in Victoria. The investment by one of the world’s leading pharmaceutical companies will create 58 new highly-skilled jobs by 2017

(more…)

GSK joins new global partnership to help defeat ten neglected tropical diseases by 2020

Industry news, News / 30 January 2012 / GlaxoSmithKline

GlaxoSmithKline (GSK) today announced it has joined other global pharmaceutical companies and leading organisations including the World Health Organization (WHO), the Bill & Melinda Gates Foundation, the UK Department for International Development and the US Agency for International Development (USAID) in a new united effort to support developing countries to defeat neglected tropical diseases (NTDs). NTDs affect more than one billion people in developing countries, causing illness, disability and death, and increasing the burden on over-stretched health systems.1

(more…)

GSK announces changes to the Board

Industry news, News / 27 January 2012 / GlaxoSmithKline

GlaxoSmithKline plc today announced that at the company’s Annual General Meeting (AGM) in 2013, following nine years of respective service to the GSK Board, Sir Crispin Davis, Sir Robert Wilson and Mr Larry Culp will not stand for re-election to the Board.

(more…)

GSK responds to the recent court ruling on the COMPAS study in Mendoza, Argentina

Industry news, News / 11 January 2012 / GlaxoSmithKline

GlaxoSmithKline respectfully disagrees with the recent court ruling in favour of ANMAT (the Argentinean National Administration of Medicines, Food and Medical Technology) on the fine issued to GSK regarding the administrative conduct of the COMPAS (Clinical Otitis Media and PneumoniA Study) study in Mendoza, Argentina. The fine issued by ANMAT relates to administrative procedures in place for the COMPAS study in 2007 and 2008. It does not question the safety of the study vaccine, Synflorix. GSK is initiating an appeal against this ruling to the Supreme Court of Argentina.

(more…)

GSK and Theravance announce initial outcomes from pivotal Phase III studies

Industry news, News / 9 January 2012 / GlaxoSmithKline

GlaxoSmithKline (GSK) and Theravance, Inc. (NASDAQ: THRX) today announced the completion of the phase III registration programme for the once-daily investigational medicine Relovair™* (fluticasone furoate “FF”/vilanterol “VI”) in patients with chronic obstructive pulmonary disease (COPD) and of all but one of the pivotal studies in patients with asthma.

(more…)

GSK extends pneumococcal vaccine agreement with GAVI Alliance

Industry news / 19 December 2011 / GlaxoSmithKline

GSK today announced it has expanded its agreement with the GAVI Alliance in a move to help protect millions more children in the world’s poorest countries from pneumococcal disease. Pneumococcal disease can lead to pneumonia, meningitis and sepsis and is a leading cause of death in children under the age of five in developing countries. (more…)

GlaxoSmithKline and Human Genome Sciences initiate phase III trial of belimumab (Benlysta®) administered subcutaneously in subjects with systemic lupus erythematosus

Industry news, News / 15 December 2011 / GlaxoSmithKline

GlaxoSmithKline (GSK) and Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that dosing has been initiated in BLISS-SC, a new Phase III trialto evaluate the efficacy, safety and tolerability of BENLYSTA® (belimumab) administered subcutaneously (SC) once-weekly to autoantibody-positive adults with active systemic lupus erythematosus (SLE).

(more…)

Drug discovery leaders roundtable

Latest issue / 13 December 2011 / Andrew A. Parsons, Vice President Preclinical Drug Development, GlaxoSmithKline and Steve Street, Vice President, Head of Research Centres of Emphasis, Head of WRD Continuous Improvement, Pfizer and William Strohl, Vice President of Biologics Research, Centocor R&D, a division of Johnson & Johnson Pharmaceutical Research & Development and Eckhard von Keutz, Senior Vice President, Head Global Early Development, Bayer HealthCare

Andrew A. Parsons, Vice President Preclinical Drug Development, GlaxoSmithKline

Dr. Parsons has led the Preclinical Development function in the CEDD since its creation. He was previously the Head of Preclinical Development for the Neurology and Gastrointestinal (NGI) Center of Excellence for Drug Discovery (CEDD) and a member of the Executive Leadership Team. Dr. Parsons joined SmithKline Beecham in 1991 as a lead biologist on the Migraine Program and played a key role in the identification and development of Frovatriptan and Tonabersat. He has worked in a number of therapy areas within drug discovery and has led teams that progressed numerous compounds in development. He was also previously the Chairman of the Imitrex (Sumatriptan) International Scientific Advisory Board. Dr. Parsons graduated with a BSc, MSc and PhD in Pharmacology, University of Manchester and is a qualified NLP practitioner and Cognitive Therapist. He worked as a post-doctoral researcher at the Institute of Physiology, University of Munich, Germany. He has authored more than 90 peer-reviewed publications.

Steve Street, Vice President, Head of Research Centres of Emphasis, Head of WRD Continuous Improvement, Pfizer

Steve Street joined Pfizer in 1985 and held a variety of roles within the Chemistry Department in Sandwich UK, before being appointed Head of Chemistry for Sandwich Discovery in 2001. Three years later, at the start of 2004, Steve moved to establish and lead the Chemistry discipline across Worldwide Discovery. Steve held this role through to early 2007 when he was delighted to be asked to take on a new role as Head of the Research Centers of Emphasis, covering a range of activities supporting Worldwide Research including External Research, BioImaging, Computational Sciences and High Throughput Screening. In April 2008, Steve was asked to become Head of Continuous Improvement across all of Pfizer Worldwide Research and Development where his focus was uniquely on improving project and portfolio survival and cycle times. (more…)

GSK presents phase lll data for lapatinib at San Antonio breast cancer symposium

Industry news, News / 8 December 2011 / GlaxoSmithKline

Results from TEACH (Tykerb Evaluation After Chemotherapy) were presented today at the 2011 CRTC-AACR San Antonio Breast Cancer Symposium. TEACH is a randomised, double-blind, placebo-controlled Phase III trial to evaluate the effects of lapatinib monotherapy when given to women who were diagnosed with HER2 positive breast cancer, received treatment excluding trastuzumab, and remained disease free. The median time from diagnosis to study entry was 3 years. Use of lapatinib in the delayed adjuvant setting is investigational only and not approved by regulatory authorities anywhere in the world.

(more…)

GSK statement in response to the Prime Minister’s speech on life sciences

Industry news, News / 5 December 2011 / GlaxoSmithKline

“The Government’s strategy for Life Sciences is a very important next step on the journey to make the UK the best place in the world to locate pharmaceutical investment. The actions on research and manufacturing will further strengthen the attractiveness of the UK and most importantly the results of the Innovation Review should ensure that the NHS is a stronger adopter of innovative medicines and technology, ensuring that all patients can benefit from cost-effective treatments and interventions approved by NICE.

(more…)

GlaxoSmithKline welcomes innovative knowledge-sharing collaboration to break deadlock in antibiotic discovery and development

Industry news, News / 17 November 2011 / GlaxoSmithKline

GlaxoSmithKline (GSK) today welcomes the European Commission’s commitment to promote collaborative research efforts to develop new antibiotics against the growing threat from resistant bacteria.

(more…)

GSK welcomes GAVI Alliance decision to introduce vaccines against cervical cancer and rubella in the world’s poorest countries

Industry news, News / 17 November 2011 / GlaxoSmithKline

GlaxoSmithKline today welcomed the decision of the GAVI Board to provide funding to facilitate the provision of cervical cancer immunisation programmes and rubella vaccination, across the world’s poorest countries.

(more…)